Primary cutaneous T-cell lymphoma of unspecified type with cytotoxic phenotype: Clinicopathological analysis of 27 patients

Cancer Science

Volumn 100, Issue 1, 2009, Pages 33-41

  Hagiwara, Masahiro ^a   Takata, Katsuyoshi ^b   Shimoyama, Yoshie ^c   Yamamoto, Kazuhito ^d   Takahashi, Emiko ^e   Asano, Naoko ^f   Iwase, Yuko ^g   Okazaki, Yoshiko ^h   Tamada, Yasuhiko ^e   Yoshino, Tadashi ^b   Tomita, Yasushi ^a   Nakamura, Shigeo ^c  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e AICHI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^f SHINSHU UNIVERSITY HOSPITAL   (Japan)

^g Department of Dermatology   (Japan)

^h Department of Clinical Laboratory   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

T LYMPHOCYTE RECEPTOR;

ADULT; AGED; ARTICLE; CANCER SURVIVOR; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; EPSTEIN BARR VIRUS; FEMALE; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; MALE; MOLECULAR BIOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PHENOTYPE; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 58149313665     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.01000.x     Document Type: Article

References (39)

1. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.
2. Yamashita Y, Yatabe Y, Tsuzuki T et al. Perforin and granzyme expression in cytotoxic T-cell lymphomas. Mod Pathol 1998; 11: 313-23.
3. De Bruin PC, Kummer JA, Van der Valk P et al. Granzyme B expressing peripheral T-cell lymphomas: Neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization. Blood 1994; 84: 3785-91.
4. Bladergroen BA, Strik MC, Wolbink AM. The granzyme B inhibitor proteinase inhibitor 9 (PI9) is expressed by human mast cells. Eur J Immunol 2005; 35: 1175-83.
5. Felgar RE, Macon WR, Kinney MC et al. TIA-1 expression in lymphoid neoplasm: Identification of subsets with cytotoxic T lymphocyte or natural killer cell differentiation. Am J Pathol 1997; 150: 1893-900.
6. Ghobrial IM, Weenig RH, Pittlekow MR et al. Clinical outcome of patients with subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma 2005; 46: 703-8.
7. Hoque SR, Child FJ, Whittaker SJ et al. Subcutaneous panniculitis-like T-cell lymphoma: A clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol 2003; 148: 516-25.
8. Ma L, Bandarchi B, Glusac EJ et al. Fatal subcutaneous panniculitis-like T-cell lymphoma with interface change and dermal mucin, a dead ringer for lupus erythematosus. J Cutan Pathol 2005; 32: 360-5.
9. + natural killer-cell lymphoma with primary cutaneous manifestation. Acta Derm Venereol 2004; 84: 53-6.
10. Chattopadhyay A, Slater DN, Hancock BW et al. Cutaneous CD56 positive natural killer and cytotoxic T-cell lymphomas. Int J Oncol 2005; 26: 1559-62.
11. + nasal-type T/ natural killer-cell subcutaneous panniculitic lymphoma: Presentation as haemophagocytic syndrome. Br J Dermatol 1999; 141: 706-9.
12. Slater DN. New CD56 positive and cytotoxic T-cell cutaneous lymphomas from the World Health Organisation. Br J Dermatol 2003; 148: 385-7.
13. Warnnissorn N, Kanitsap N, Kulkantrakorn K et al. Natural killer cell malignancy associated with Epstein-Barr virus and hemophagocytic syndrome. J Med Assoc Thai 2007; 90: 982-7.
14. + large cell lymphoma: Definition of a new type of cutaneous lymphoma with a favorable prognosis. A European Multicenter Study of 47 patients. Cancer 1993; 71: 2097-104.
15. Kadin ME, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hemato 2003; 40: 244-56.
16. + cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 2003; 49: 1049-58.
17. Paulli M, Berti E, Rosso R et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin - clinicopathologic correlation and statistical analysis of 86 cases: A multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol 1995; 13: 1343-54.
18. + anaplastic large cell lymphoma: A review of its histopathologic, genetic, and clinical features. Blood 2000; 96: 3681-95.
19. + lymphoproliferative disorders: A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 1993; 28: 973-80.
20. Toro JR, Liewehr DJ, Pabby N et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003; 101: 3407-12.
21. Massone C, Chott A, Metze D et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, other cytotoxic lymphomas of the skin: A morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol 2004; 28: 719-35.
22. McCarthy KP, Sloane JP, Kabarowski JHS et al. A simplified method of detection of clonal rearrangements of the T-cell receptor-γ chain gene. Diagn Mol Pathol 1992; 1: 173-9.
23. Gallamini A, Stelitano C, Calvi R et al. Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474-9.
24. Avinoach I, Halevy S, Argov S et al. Gamma/delta T-cell lymphoma involving the subcutaneous tissue and associated with a hemophagocytic syndrome. Am J Dermatopathol 1994; 16: 426-33.
25. Toro JR, Beaty M, Sorbara L et al. Gamma delta T-cell lymphoma of the skin: A clinical, microscopic, and molecular study. Arch Dermatol 2000; 136: 1024-32.
26. Ralfkiaer E, Wolf-Sneedorff A, Thomsen K et al. T-cell receptor gamma delta-positive peripheral T-cell lymphomas presenting in the skin: A clinical, histological and immunophenotypic study. Exp Dermatol 1992; 1: 31-6.
27. Ishida T, Inagaki H, Utsunomiya A et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 2004; 10: 5494-500.
28. Berti E, Tomasini D, Vermeer MH et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999; 155: 483-92.
29. Fika Z, Karkos PD, Badran K et al. Primary cutaneous aggressive epidermotropic CD8 positive cytotoxic T-cell lymphoma of the ear. J Laryngol Otol 2007; 121: 503-5.
30. + cytotoxic T-cell lymphoma with atypical presentation. J Dermatol 2006; 33: 632-4.
31. + epidermotropic cytotoxic primary cutaneous T-cell lymphoma with multiorgan involvement. Dermatol 2005; 211: 285.
32. + epidermotropic cytotoxic T-cell lymphoma with aggressive course.] Ann Dermatol Venereol 2006; 133: 253-6.
33. Petrella T, Maubec E, Cornillet-Lefebvre P et al. Indolent CD8-positive lymphoid proliferation of the ear: A distinct primary cutaneous T-cell lymphoma? Am J Surg Pathol 2007; 31: 1887-92.
34. Juarez T, Isenhath SN, Polissar NL et al. Analysis of T-cell receptor gene rearrangement for predicting clinical outcome in patients with cutaneous T-cell lymphoma: A comparison of Southern blot and polymerase chain reaction methods. Arch Dermatol 2005; 141: 1107-13.
35. Asano N, Suzuki R, Kagami Y et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol 2005; 29: 1284-93.
36. Belhadj K, Reyes F, Farcet JP et al. Hepatosplenic γ/δ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003; 102: 4261-9.
37. Cooke CB, Krenacs L, Stetler-Stevenson M et al. Hepatosplenic T-cell lymphoma: A distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin. Blood 1996; 88: 4265-74.
38. Daum S, Foss HD, Anagnostopoulos I et al. Expression of cytotoxic molecules in intestinal T-cell lymphomas. The German Study Group on Intestinal Non-Hodgkin Lymphoma. J Pathol 1997; 182: 311-17.
39. De Bruin PC, Kummer JA, Van der Valk P et al. Granzyme B expressing peripheral T-cell lymphomas: Neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization. Blood 1994; 84: 3785-91.